Does epidermal growth factor play a role in the action of sucralfate?
Epidermal growth factor (EGF) is a mitogenic peptide synthesized in the submandibular glands and released in saliva. EGF is able to prevent the development of gastrointestinal ulcers in the rat and to accelerate their healing. The present work was undertaken to examine whether Sucralfate acts via the effector system of EGF. We conclude that Sucralfate does not change the binding of EGF to its receptor, but it is able to bind EGF in a pH dependent manner and at pH below 4.5 virtually all EGF is bound to Sucralfate. In vivo studies in rats with acid-induced gastric ulcers show that sucralfate carries EGF to the ulcer, and that EGF is available for a longer period of time (3 hours) when EGF and Sucralfate are is given together than when EGF is given alone.
D000818:Animals; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D013276:Stomach Ulcer / Q000378:metabolism* / Q000473:pathology; D013392:Sucralfate / Q000494:pharmacology*
D013392:Sucralfate; D004815:Epidermal Growth Factor; D066246:ErbB Receptors